Extended Data Fig. 2. Antibody drug evasion and hACE2 binding capability of convergent Omicron variants.

a, IC50 of therapeutic NAbs against pseudoviruses of additional emerging SARS-CoV-2 Omicron subvariants. b, Relative hACE2-binding capability measured by IC50 of hACE2 against pseudoviruses. Error bars indicate mean ± s.d. of n = 5 biologically independent replicates. P-values were calculated using a two-tailed Student’s t-test. *, p < 0.05; **, p < 0.01; ***, p < 0.001. No label on variants with p > 0.05. Variants with significantly stronger binding are coloured blue, while those with weaker binding are coloured red. All neutralization assays were conducted in at least two independent experiments.